[Market Access and Pricing Opportunities project]• Analyzed the latest issued guidelines of the disease burden and treatment pathway of generalized myasthenia gravis of 5 countries, and identified key clinical unmet needs for subgroups to facilitate expert interview and outline designing • Conducted 4 expert interviews with physicians, assessed the perceived level of therapeutic improvement of product X in generalized myasthenia gravis, and dug out the competitive advantages to help win a premium in the NRDL inclusion pricing• Positioned product X after analyzing the suggestions from payers, benchmarked 6 competitors in 3 different scenarios to formulate price potentials, and derived early access opportunity to enter[Dual-channel Policy Deep Dive project]• Investigated patient access improvement under the policy, organized dual-channel formulary listing criteria and process to propose underlying imperatives and challenges for the pharma using visualization in combined PowerPoint presentation • Performed a case study and illustrated the significant challenge for products arising from implementation deviation at the grassroots level

• Leveraged Excel to systematize the bidding rules, and differences among batches of national volume-based procurement (VoBP) in rules tendency, implementation time, and price reduction rate to appraise the price cut of product Y once included in the VoBP• Collected epidemiological data from 50+ studies from PubMed, The Lancet, and Wanfang Med Online databases, evaluated from indexes including prevalence, disease segmentation, and treatment rates to estimate the addressable patient base in China

• Developed a list of authoritative experts in the field of retinitis pigmentosa and ranked the experts based on both academic performance and clinical trial participation to assist the client in prioritizing their sales force and enhance the probability of engaging the appropriate hospitals and KOLs actively• Extracted secondary data from PharmCube, Yaozhi Net, yearly NRDL, calculated annual treatment costs of drugs whose indication includes hepatocellular carcinoma of product Z at various reimbursement stages to compute the average price cut and make revenue projections of product Z